The announcement of a class action lawsuit against Kyverna Therapeutics for alleged securities violations related to their IPO is likely to create negative sentiment among investors. Legal issues can lead to uncertainty and potential financial liabilities, which often result in a decline in stock prices. Given the direct involvement of the company and its officers, the relevance and importance of this news are high, and the short-term impact on the stock price is likely negative.